Clinical pharmacology of cytarabine in patients with acute myeloid leukemia

a Cancer and Leukemia Group B study

Ronald A. Fleming, Robert L. Capizzi, Gary Rosner, Lawrence K. Oliver, Stephen J. Smith, Charles A. Schiffer, Richard T. Silver, Bruce A. Peterson, Raymond B. Weiss, George A. Omura, Robert J. Mayer, David A. Van Echo, Clara D. Bloomfield, Richard L. Schilsky

Research output: Contribution to journalArticle

Abstract

The pharmacokinetics of cytarabine (ara-C) were determined in 265 patients with acute myeloid leukemia (AML) receiving ara-C (200 mg/m2 per day for 7 days as a continuous infusion) and daunorubicin during induction therapy. The mean (standard deviation) ara-C concentration at steady-state (Css) and systemic clearance (Cl) were 0.30 (0.13) μM and 134 (71) l/h per m2 respectively. Males had a significantly faster ara-C Cl (139 vs 131 l/h per m2, P=0.025) than females. Significant correlations were noted between ara-C Cl and the pretreatment, peripheral white blood cell count (P=0.005) and pretreatment blast count (P=0.020). No significant differences in ara-C Css or Cl were noted in patients achieving complete remission compared with those failing therapy (P=0.315, P=0.344, respectively). No significant correlations were observed between ara-C pharmacokinetic parameters and several indices of patient toxicity. Our findings indicate that variability in ara-C disposition in plasma at this dosage level does not correlate with remission status or toxicity in patients with AML receiving initial induction therapy with ara-C and daunorubicin.

Original languageEnglish (US)
Pages (from-to)425-430
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Volume36
Issue number5
DOIs
StatePublished - Sep 1995
Externally publishedYes

Fingerprint

Clinical Pharmacology
Cytarabine
Acute Myeloid Leukemia
Leukemia
Neoplasms
Daunorubicin
Pharmacokinetics
Toxicity
Leukocyte Count
Blood
Therapeutics
Cells
Plasmas

Keywords

  • Cytarabine
  • Leukemia

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Clinical pharmacology of cytarabine in patients with acute myeloid leukemia : a Cancer and Leukemia Group B study. / Fleming, Ronald A.; Capizzi, Robert L.; Rosner, Gary; Oliver, Lawrence K.; Smith, Stephen J.; Schiffer, Charles A.; Silver, Richard T.; Peterson, Bruce A.; Weiss, Raymond B.; Omura, George A.; Mayer, Robert J.; Van Echo, David A.; Bloomfield, Clara D.; Schilsky, Richard L.

In: Cancer Chemotherapy and Pharmacology, Vol. 36, No. 5, 09.1995, p. 425-430.

Research output: Contribution to journalArticle

Fleming, RA, Capizzi, RL, Rosner, G, Oliver, LK, Smith, SJ, Schiffer, CA, Silver, RT, Peterson, BA, Weiss, RB, Omura, GA, Mayer, RJ, Van Echo, DA, Bloomfield, CD & Schilsky, RL 1995, 'Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a Cancer and Leukemia Group B study', Cancer Chemotherapy and Pharmacology, vol. 36, no. 5, pp. 425-430. https://doi.org/10.1007/BF00686192
Fleming, Ronald A. ; Capizzi, Robert L. ; Rosner, Gary ; Oliver, Lawrence K. ; Smith, Stephen J. ; Schiffer, Charles A. ; Silver, Richard T. ; Peterson, Bruce A. ; Weiss, Raymond B. ; Omura, George A. ; Mayer, Robert J. ; Van Echo, David A. ; Bloomfield, Clara D. ; Schilsky, Richard L. / Clinical pharmacology of cytarabine in patients with acute myeloid leukemia : a Cancer and Leukemia Group B study. In: Cancer Chemotherapy and Pharmacology. 1995 ; Vol. 36, No. 5. pp. 425-430.
@article{57671ab752b342f0bb7f2a05d117f57c,
title = "Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a Cancer and Leukemia Group B study",
abstract = "The pharmacokinetics of cytarabine (ara-C) were determined in 265 patients with acute myeloid leukemia (AML) receiving ara-C (200 mg/m2 per day for 7 days as a continuous infusion) and daunorubicin during induction therapy. The mean (standard deviation) ara-C concentration at steady-state (Css) and systemic clearance (Cl) were 0.30 (0.13) μM and 134 (71) l/h per m2 respectively. Males had a significantly faster ara-C Cl (139 vs 131 l/h per m2, P=0.025) than females. Significant correlations were noted between ara-C Cl and the pretreatment, peripheral white blood cell count (P=0.005) and pretreatment blast count (P=0.020). No significant differences in ara-C Css or Cl were noted in patients achieving complete remission compared with those failing therapy (P=0.315, P=0.344, respectively). No significant correlations were observed between ara-C pharmacokinetic parameters and several indices of patient toxicity. Our findings indicate that variability in ara-C disposition in plasma at this dosage level does not correlate with remission status or toxicity in patients with AML receiving initial induction therapy with ara-C and daunorubicin.",
keywords = "Cytarabine, Leukemia",
author = "Fleming, {Ronald A.} and Capizzi, {Robert L.} and Gary Rosner and Oliver, {Lawrence K.} and Smith, {Stephen J.} and Schiffer, {Charles A.} and Silver, {Richard T.} and Peterson, {Bruce A.} and Weiss, {Raymond B.} and Omura, {George A.} and Mayer, {Robert J.} and {Van Echo}, {David A.} and Bloomfield, {Clara D.} and Schilsky, {Richard L.}",
year = "1995",
month = "9",
doi = "10.1007/BF00686192",
language = "English (US)",
volume = "36",
pages = "425--430",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Clinical pharmacology of cytarabine in patients with acute myeloid leukemia

T2 - a Cancer and Leukemia Group B study

AU - Fleming, Ronald A.

AU - Capizzi, Robert L.

AU - Rosner, Gary

AU - Oliver, Lawrence K.

AU - Smith, Stephen J.

AU - Schiffer, Charles A.

AU - Silver, Richard T.

AU - Peterson, Bruce A.

AU - Weiss, Raymond B.

AU - Omura, George A.

AU - Mayer, Robert J.

AU - Van Echo, David A.

AU - Bloomfield, Clara D.

AU - Schilsky, Richard L.

PY - 1995/9

Y1 - 1995/9

N2 - The pharmacokinetics of cytarabine (ara-C) were determined in 265 patients with acute myeloid leukemia (AML) receiving ara-C (200 mg/m2 per day for 7 days as a continuous infusion) and daunorubicin during induction therapy. The mean (standard deviation) ara-C concentration at steady-state (Css) and systemic clearance (Cl) were 0.30 (0.13) μM and 134 (71) l/h per m2 respectively. Males had a significantly faster ara-C Cl (139 vs 131 l/h per m2, P=0.025) than females. Significant correlations were noted between ara-C Cl and the pretreatment, peripheral white blood cell count (P=0.005) and pretreatment blast count (P=0.020). No significant differences in ara-C Css or Cl were noted in patients achieving complete remission compared with those failing therapy (P=0.315, P=0.344, respectively). No significant correlations were observed between ara-C pharmacokinetic parameters and several indices of patient toxicity. Our findings indicate that variability in ara-C disposition in plasma at this dosage level does not correlate with remission status or toxicity in patients with AML receiving initial induction therapy with ara-C and daunorubicin.

AB - The pharmacokinetics of cytarabine (ara-C) were determined in 265 patients with acute myeloid leukemia (AML) receiving ara-C (200 mg/m2 per day for 7 days as a continuous infusion) and daunorubicin during induction therapy. The mean (standard deviation) ara-C concentration at steady-state (Css) and systemic clearance (Cl) were 0.30 (0.13) μM and 134 (71) l/h per m2 respectively. Males had a significantly faster ara-C Cl (139 vs 131 l/h per m2, P=0.025) than females. Significant correlations were noted between ara-C Cl and the pretreatment, peripheral white blood cell count (P=0.005) and pretreatment blast count (P=0.020). No significant differences in ara-C Css or Cl were noted in patients achieving complete remission compared with those failing therapy (P=0.315, P=0.344, respectively). No significant correlations were observed between ara-C pharmacokinetic parameters and several indices of patient toxicity. Our findings indicate that variability in ara-C disposition in plasma at this dosage level does not correlate with remission status or toxicity in patients with AML receiving initial induction therapy with ara-C and daunorubicin.

KW - Cytarabine

KW - Leukemia

UR - http://www.scopus.com/inward/record.url?scp=0028984050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028984050&partnerID=8YFLogxK

U2 - 10.1007/BF00686192

DO - 10.1007/BF00686192

M3 - Article

VL - 36

SP - 425

EP - 430

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 5

ER -